10-Q: Azenta Q1 2026: Strategic Divestiture, Mixed Financials

Azenta, Inc. reports a net loss of $15.4 million in Q1 2026, driven by a loss on assets held for sale, while advancing its strategic divestiture of the B Medical Systems business.

Summary

• Net loss for the three months ended December 31, 2025, was $(15.4) million, compared to $(11.0) million for the corresponding period in the prior fiscal year.
• Total revenue increased 0.8% to $148.6 million in Q1 2026 from $147.4 million in Q1 2025.
• Loss from discontinued operations, net of tax, was $(10.2) million in Q1 2026, primarily due to a $9.7 million loss on assets held for sale related to the B Medical Systems business.
• Gross profit decreased to $63.7 million (43% gross margin) in Q1 2026 from $68.8 million (47% gross margin) in Q1 2025.
• Operating expenses decreased by $6.6 million to $70.9 million, mainly due to lower selling, general, and administrative (SG&A) expenses.
• Multiomics segment revenue increased approximately 1%, but its operating loss widened to $(5.0) million from $(3.2) million.
• Sample Management Solutions segment revenue was flat, with operating income decreasing to $3.7 million from $4.0 million.
• Cash and cash equivalents, restricted cash, and marketable securities totaled $570.9 million as of December 31, 2025.
• The Board approved a new share repurchase program of up to $250 million through December 31, 2028.
• Material weaknesses in internal control over financial reporting remain outstanding, related to cash flow statement review, account reconciliations, and expense classification.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed quarter with strategic progress on divestiture but significant financial underperformance, particularly the widening net loss and declining gross margin, coupled with persistent internal control weaknesses.

Positives

• Total revenue increased by 0.8% to $148.6 million, driven by growth in the Multiomics segment.
• Operating expenses decreased by $6.6 million, primarily due to lower selling, general, and administrative expenses.
• Net loss from continuing operations improved to $(5.2) million from $(7.1) million in the prior year.
• Interest income, net, increased to $5.1 million from $4.3 million due to increased investments in marketable securities.
• A new share repurchase program of up to $250 million was approved, signaling confidence in future cash flow.
• Cash and cash equivalents, restricted cash, and marketable securities increased to $570.9 million from $546.2 million at September 30, 2025.

Negatives

• Net loss widened to $(15.4) million from $(11.0) million in the prior year.
• Loss from discontinued operations, net of tax, significantly increased to $(10.2) million, primarily due to a $9.7 million loss on assets held for sale.
• Gross margin decreased to 43% from 47% in the prior year, attributed to lost cost leverage from lower North America sales volume for Sanger Sequencing and higher rework costs on Automated Stores projects.
• Multiomics segment operating loss widened to $(5.0) million from $(3.2) million, and adjusted operating margin decreased by 300 basis points.
• Sample Management Solutions segment revenue was flat, and operating income decreased to $3.7 million from $4.0 million.
• Restructuring charges increased to $1.1 million from $0.4 million in the prior year.
• Foreign currency transaction and remeasurement resulted in net losses of $0.9 million compared to gains of $0.5 million in the prior year.

Risks

• Thelema S. R.L. may fail to secure the remaining $54.0 million financing for the B Medical Systems business acquisition by March 31, 2026, which could require Azenta to continue operating the business, leading to negative and dilutive impacts on performance, management distraction, and potential additional impairment charges.
• An ongoing legal dispute with Edwards Vacuum LLC regarding the semiconductor cryogenics business sale in 2019, with an accrued liability of $2.1 million as of December 31, 2025, could result in an adverse outcome materially affecting financial position or results.
• Material weaknesses in internal control over financial reporting remain outstanding, specifically related to cash flow statement review, account reconciliations, and expense classification, which could lead to material misstatements not being prevented or detected timely.
• Exposure to market risks, including changes in interest rates affecting investments and fluctuations in foreign currency exchange rates.
• Inability to obtain financing on favorable terms if required, which could hinder product development, competitive response, or acquisition opportunities.

Future Outlook

Azenta expects to complete the sale of the B Medical Systems business by March 31, 2026, contingent on the acquirer securing final residual financing. The company anticipates completing its 2024 Restructuring Plan activities by the end of fiscal year 2026. Azenta will adopt ASU 2023-09 for the year ended September 30, 2026, which will enhance income tax disclosures without impacting financial position or results. The company is evaluating the impact of ASU 2024-03 and ASU 2025-06. Azenta does not expect the "One Big Beautiful Bill Act" tax law changes to impact its effective tax rate or cash flows in the near term. Management believes current cash and cash equivalents will fund operating expenses and capital expenditure requirements for at least one year and for the foreseeable future thereafter.

Management Comments

• "This strategic action [B Medical Systems divestiture] is intended to simplify our portfolio and allow management to focus on driving revenue growth and profitability in our core Sample Management Solutions and Multiomics segments."
• "We are committed to continuing to improve our internal control over financial reporting, and as we continue to evaluate and work to improve our internal control over financial reporting, we may take additional measures to address control deficiencies, or we may modify certain of the remediation measures described above."

Industry Context

StockSavvy.ai notes that Azenta's strategic divestiture of the B Medical Systems business aligns with a broader industry trend of life sciences companies streamlining portfolios to focus on high-growth, core competencies like sample management and multiomics. The slight revenue growth in Multiomics, despite a decline in Sanger Sequencing, indicates a shift towards next-generation technologies, a common theme in the genomics sector. The flat performance in Sample Management Solutions suggests a mature market or increased competition, while the focus on cost reduction and productivity improvement through transformation initiatives is a common response to margin pressures across various industries.

Comparison to Industry Standards

• No specific comparable companies, projects, or results for direct comparison are mentioned in the filing.

Management Changes

Corporate Governance

Legal Proceedings

• Ongoing dispute with Edwards Vacuum LLC regarding the sale of the semiconductor cryogenics business in July 2019, with an accrued liability of $2.1 million as of December 31, 2025. The Company's motion to dismiss Edwards' lawsuit filed on September 12, 2025, is pending.
• Subject to various other legal proceedings in the ordinary course of business, but no new material provision for liability or disclosure is required as of December 31, 2025.

Related Party Transactions

• The sale of the B Medical Systems business to Thelema S. R.L. is a related party transaction, as a current Vice President of Azenta and CEO of the B Medical Systems business is Thelema's majority owner. The terms were negotiated on an arms-length basis following a competitive auction process.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value through the new $250 million share repurchase program. However, the widening net loss, declining gross margin, and outstanding material weaknesses could negatively impact investor confidence and share price. The uncertainty around the B Medical Systems divestiture completion also poses a risk.
• Employees: The 2024 Restructuring Plan involves initiatives to optimize resources and improve efficiency, which could include workforce adjustments. Stock-based compensation plans continue to be a part of employee incentives.
• Customers: The focus on core Sample Management Solutions and Multiomics segments aims to drive revenue growth and profitability, potentially leading to enhanced product and service offerings in these areas. Higher rework costs on Automated Stores projects might indicate temporary customer satisfaction issues in that specific area.
• Creditors: No outstanding debt on the balance sheet, indicating a strong liquidity position for continuing operations.

Next Steps

• Complete the sale of the B Medical Systems business by March 31, 2026, contingent on buyer financing.
• Continue to implement and evaluate remediation plans for material weaknesses in internal control over financial reporting.
• Continue to execute the 2024 Restructuring Plan, with completion expected by the end of fiscal year 2026.
• Monitor the financial impact of the "One Big Beautiful Bill Act" tax law changes.
• Evaluate the impact of new accounting standards (ASU 2024-03, ASU 2025-06) on consolidated financial statements.
• Potentially repurchase up to $250 million of common stock under the new program through December 31, 2028.

Key Dates

Recommendation

Azenta's Q1 2026 results present a mixed picture that warrants a "hold" recommendation. While the strategic divestiture of the B Medical Systems business and the new $250 million share repurchase program are positive signals for long-term portfolio focus and capital allocation, the immediate financial performance is concerning. The widening net loss, significant decline in gross margin, and persistent material weaknesses in internal controls indicate operational challenges that need to be addressed. The uncertainty surrounding the completion of the B Medical Systems sale also adds a layer of risk. Investors should monitor the successful execution of the divestiture, the remediation of internal control issues, and improvements in core segment profitability before considering a stronger position.

Keywords

Life sciences, Sample management, Multiomics, Genomic services, Automated storage, Cryogenic systems, Biotechnology, Pharmaceutical, SEC filing, 10-Q, Divestiture, Share repurchase, Internal controls